Trials / Completed
CompletedNCT02278588
Effect of 2.5 Years of Rasagiline Therapy on Progression of Cognitive Biomarkers Assessed by MRI in Parkinson's Disease.
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 45 (actual)
- Sponsor
- State University of New York at Buffalo · Academic / Other
- Sex
- All
- Age
- —
- Healthy volunteers
- Accepted
Summary
In this investigator-initiated study, we will compare changes in brain cognitive biomarkers assessed by diffusion tensor imaging over 2.5 years among 12 patients with Idiopathic Parkinson's disease (IPD) receiving rasagiline, 20 IPD patients not receiving MAO-B inhibitors and 25 age-matched healthy controls. Will also compare the changes in Mini-Mental State Exam (MMSE) and Montreal Cognitive Assessment (MoCA) scores and plasma brain-derived neurotrophic factor (BDNF) with changes in brain cognitive biomarkers in all IPD patients and HC over 2.5 years.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Rasagiline |
Timeline
- Start date
- 2014-11-01
- Primary completion
- 2017-12-01
- Completion
- 2017-12-01
- First posted
- 2014-10-30
- Last updated
- 2023-02-14
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT02278588. Inclusion in this directory is not an endorsement.